ProCE Banner Activity

Evidence-Based Treatment for ALK and ROS1 Rearrangement–Positive NSCLC

Slideset Download
In this downloadable slideset, Alice T. Shaw, MD, PhD, highlights key studies for optimizing the management of patients with advanced-stage ALK and ROS1 rearrangement–positive NSCLC.

Released: December 22, 2016

Expiration: December 21, 2017

Share

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

Celgene

Genentech Roche Virology

Lilly

Merck Oncology

Novartis Pharmaceuticals Corporation